Valeant Pharmaceuticals Receives Lender Consent For Credit Facility Amendment
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Valeant's (VRX) Amended Facility Expected, But Shares Remain Uninvestible - Piper
August 19, 2016 6:39 AM EDTPiper Jaffray affirms Valeant Pharma (NYSE: VRX) with an Underweight rating and $22 price target following news that the company entered an amended credit facility.
Analyst David Amsellem commented today:
Valeant shares have been strong of late, ostensibly in anticipation of an amendment to the companys credit facility (which was announced on Thursday) that gives the company more breathing room as it looks to stabilize and turn around key segments and sell off non-core assets... More
RBC Capital Remains Sidelined as Valeant Pharma (VRX) Announces Credit Amendment
August 18, 2016 11:15 AM EDTRBC Capital reiterated a Sector Perform rating and $36.00 price target on Valeant Pharmaceuticals (NYSE: VRX) following the company's announcement that is has agreed to amend terms with its lenders. This decision comes on the heels of VRX's Aug 12th announcement that the company would... More
